Close

Publications

VASSALL, A; Masiye, F;
2022
BMJ (Clinical research ed.), (2022).378, 10.1136/bmj.o2320.
Fentress, M; Henwood, PC; Maharaj, P; Mitha, M; Khan, D; Caligiuri, P; Karat, AS; Olivier, S; Edwards, A; Ramjit, D; Ngcobo, N; Wong, EB; GRANT, AD;
2022
PLOS global public health, (2022).2 10 10.1371/journal.pgph.0000800.
NATUKUNDA, A; ZIRIMENYA, L; Nassuuna, J; NKURUNUNGI, G; COSE, S; ELLIOTT, AM; WEBB, EL;
2022
Parasite Immunology, (2022).44 9 10.1111/pim.12939.
Yates, TA; KHAN, PY;
2022
The Lancet. Infectious diseases, (2022).22 9 10.1016/s1473-3099(22)00454-6.
Cost-effectiveness of shortened regimens for DR-TB.
SWEENEY, S;
2022
(2022).
Alshabani, LA; Kumar, A; WILLCOCKS, SJ; Srithiran, G; Bhakta, S; Estrada, DF; Simons, C;
2022
RSC Medicinal Chemistry, (2022).13 11 10.1039/d2md00155a.
PRACTECAL regimens for MDR-TB: Preliminary cost-effectiveness analysis.
SWEENEY, S;
2022
(2022).
Puyén, ZM; Santos-Lázaro, D; Vigo, AN; Coronel, J; Alarcón, MJ; Cotrina, VV; MOORE, DA J;
2022
BMC Infectious Diseases, (2022).22 1 10.1186/s12879-022-07677-9.
Capeding, TP J; Rosa, JD; Lam, H; Gaviola, DG; Garfin, AM C; Hontiveros, C; Cunnama, L; LAURENCE, YV; Kitson, N; VASSALL, A; SWEENEY, S; Garcia-Baena, I;
2022
International Journal of Tuberculosis and Lung Disease, (2022).26 5 10.5588/ijtld.21.0622.
Dale, KD; SCHWALB, A; HOUBEN, RM G J;
2022
The Lancet Infectious diseases, (2022).22 9 10.1016/S1473-3099(22)00452-2.